# PARP

Source: https://nuclide.cc/targets/parp/  
Nuclide record `parp` (Target). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

PARP is a DNA repair enzyme. Cancers that have already lost one repair system (BRCA) die when this second one is blocked; healthy cells survive.

## Summary

PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) exploit synthetic lethality with BRCA1/2 mutations and homologous recombination deficiency in ovarian, breast, prostate, and pancreatic cancer. Olaparib is approved in adjuvant germline-BRCA breast cancer (OlympiA). PARP1-selective inhibitors (saruparib) and PARP PET tracers are the next step.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Also known as: PARP1/2; Poly [ADP-ribose] polymerase 2
- Tags: synthetic-lethality
- Symbol: PARP1
- Class: enzyme
- Biology: Poly(ADP-ribose) polymerase 1 senses single-strand breaks; trapping on DNA is the key cytotoxic mechanism.
- Where found: BRCA/HRD ovarian, breast, prostate, pancreatic cancers

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/PARP_inhibitor
- Wikipedia: https://en.wikipedia.org/wiki/PARP_inhibitor

## Connected records

- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/), [Small-cell lung cancer](https://nuclide.cc/indications/sclc/)
- technologies: [PARP PET](https://nuclide.cc/technologies/parp-pet/), [Radioligand plus DNA-repair inhibitor combinations](https://nuclide.cc/technologies/radionuclide-parp-combination/)
- drugs: [Olaparib](https://nuclide.cc/drugs/olaparib/)
- institutions: [Abramson Cancer Center, University of Pennsylvania](https://nuclide.cc/institutions/penn-abramson/)
- people: [Delphine L. Chen](https://nuclide.cc/people/delphine-chen/), [Robert H. Mach](https://nuclide.cc/people/robert-mach/)
- pairings: [177Lu-PSMA-617 (Pluvicto) with olaparib](https://nuclide.cc/pairings/pluvicto-plus-olaparib/)

---
JSON: https://nuclide.cc/api/v1/entities/parp.json